ArticleIrish journal of medical science2026
Dosimetric impact of daily MR-guided adaptive radiotherapy across different anatomical sites.
Article in Irish journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMR-guided adaptive radiotherapy (MRgART) enables daily plan adaptation to account for anatomical variations; however, its resource-intensive workflow necessitates careful patient selection, and the relative benefit across anatomical sites remains to be clearly defined.
aimTo systematically evaluate the site-dependent dosimetric impact of daily MRgART and identify anatomical regions deriving the greatest benefit from on-table adaptation.
methodsSixty-six patients treated with five-fraction SBRT on a 0.35 T MR-Linac were retrospectively analyzed: lung (n = 15), pancreas (n = 12), liver (n = 12), abdominal lymph node (n = 12), and prostate (n = 15). For each fraction, predicted and reoptimized plans were generated. Dose-volume parameters were normalized and cumulatively assessed using DVH summation. Target coverage (PTV D95, GTV/CTV D98), CI, GI, and OAR metrics were evaluated using paired Wilcoxon tests.
resultsThe largest median improvement in PTV D95 was observed in abdominal lymph node (5.3%), lung (4.4%), and prostate (4.1%) cohorts. Significant improvements in GTV/CTV D98 were observed in all sites except pancreas. CI improved significantly in all cohorts except prostate, whereas GI improvements were limited to abdominal lymph node and prostate cases. Although improvements in target coverage were limited in pancreatic cases, this subgroup demonstrated the most consistent reductions in gastrointestinal OAR doses. Lung cases showed significant improvement only in lung V20, while liver cases exhibited modest and heterogeneous OAR changes.
conclusionDaily MRgART provides site-dependent benefit, with the greatest clinical impact in pancreatic and abdominal lymph node cases. In high-volume settings, prioritization for daily adaptation may focus on these groups, followed by lung and prostate, while liver cases derive more limited benefit.
Indexed as
Identifiers
42360603What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.